Health

CVS Health on Thursday reported second-quarter earnings and revenue that topped estimates and raised its adjusted profit outlook, as it sees strength in its retail pharmacy business and some improvement in its insurance unit. Shares of the retail drugstore chain jumped more than 1% on Thursday.The company now expects fiscal 2025 adjusted earnings of $6.30 to $6.40 per share, up from previous guidance of $6 to $6.20 per share. CVS also cut its GAAP earnings guidance, without disclosing additional details.In an interview, CVS CEO David Joyner said the quarterly beat and guidance hike is in part "a tribute to the work and the effort underway within Aetna," the company's insurer. He was referring to a "multiyear recovery effort" at Aetna, which has been grappling with higher medical costs in p...

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024.Nurphoto | Nurphoto | Getty ImagesEli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.Mounjaro met the study's main goal of showing that it wasn't any worse than Trulicity at treating people with Type 2 diabetes and established cardiovascular disease. Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes, who are twice as likely to have heart disease or stroke as those without the disease.The results come as Trulicity – also a...

U.S. President Donald Trump, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, David Sacks, AI & Crypto Czar and Amy Gleason, Acting Administrator, Department of Government Efficiency (DOGE) attend the "Making Health Technology Great Again" event in the East Room at the White House in Washington, D.C., U.S., July 30, 2025. Evelyn Hockstein | ReutersPresident Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.On Truth Social on Thursday, Trump posted individual letters he sent 17 drugmakers: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, G...

The Moderna logo is seen in Warsaw, Poland, on April 9, 2025.Jakub Porzycki | Nurphoto | Getty ImagesModerna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street's expectations for the second quarter as it works to cut costs.Shares of Moderna fell more than 9% on Friday.The biotech company now expects full-year revenue to come in between $1.5 billion and $2.2 billion, down $300 million at the top of that range. The results come a day after Moderna announced plans to slash 10% of its workforce, adding to a string of cost cuts as the company grapples with falling Covid vaccine sales and tries to bring more products to market. In an interview, Moderna Chief Financial Officer Jamey Mock said instead of shipping spring ...

The Hers app arranged on a smartphone in New York on Feb. 12, 2025.Gabby Jones | Bloomberg | Getty ImagesShares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue.Here's how the company did based on average analysts' estimates compiled by LSEG:Earnings per share: 17 cents adjusted vs. 15 cents expectedRevenue: $544.8 million vs. $552 million expectedRevenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier.For its third qu...

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty ImagesPfizer on Tuesday hiked its full-year adjusted profit guidance on cost cuts and its strong business performance this year.The company also reported second-quarter results that topped Wall Street's estimates for the period, as revenue from its Covid products and some other drugs jumped.Shares of Pfizer rose more than 4% on Tuesday.Pfizer now expects full-year adjusted profit to come in between $2.90 and $3.10, up from previous guidance of $2.80 to $3 per share. The company maintained its 2025 revenue forecast of $61 billion to $64 billion."We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strat...

U.S. President Donald Trump talks to members of the press at Lehigh Valley International Airport in Allentown, Pennsylvania, U.S., August 3, 2025.Ken Cedeno | ReutersPresident Donald Trump told CNBC's "Squawk Box" on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he has threatened so far.He said he will initially impose a "small tariff" on pharmaceuticals, but then in a year to a year and a half "maximum," he will raise that rate to 150% and then 250%.The president has repeatedly threatened and then changed course on tariff proposals, so there's no guarantee he will eventually set pharmaceutical tariffs at the 250% rate. In early July, Trump had threatened 200% tariffs on pharmaceuticals.Read more from CNBC's inter...

Linda Yaccarino attends the Milken Institute Global Conference 2025 in Beverly Hills, California, on May 5, 2025.Mike Blake | ReutersLinda Yaccarino, the former chief executive of Elon Musk's social media platform X, is pivoting into health care.The digital health company eMed Population Health on Tuesday announced it has appointed Yaccarino as its new CEO. EMed is developing a population health management platform for the blockbuster weight loss and diabetes drugs called GLP-1s, the company said. It had raised a total of $22 million as of 2022, according to PitchBook.Yaccarino, who rose to the top of NBCUniversal's global advertising business before joining X, will help eMed establish "game-changing partnerships" and navigate complex markets, the company said."The healthcare industry has ...

Hinge Health co-founders, Gabriel Mecklenburg and Daniel Perez celebrate its initial public offering at the New York Stock Exchange on May 22, 2025.NYSEShares of Hinge Health popped 6% in extended trading on Tuesday after the digital physical therapy company reported quarterly results for the first time since its debut on the New York Stock Exchange in May.Here's how the company did based on average analysts' estimates compiled by LSEG:Loss: Loss per share of $13.10. That may not compare with the 9 cents per share earnings expectedRevenue: $139 million vs. $125 million expectedRevenue at Hinge increased 55% in the second quarter from $89.8 million during the same period last year, according to a release.Hinge reported a net loss of $575.65 million, or $13.10 per share, compared to a loss o...

A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | ReutersA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.For once, the Trump administration may be giving some drugmakers a reason to celebrate.The Trump administration is planning to experiment with covering costly weight loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. That plan could expand access to millions of Americans with obesity who can't currently afford Novo Nordisk's Wegovy and Eli Lilly's Zepbound, blockbuster GLP-1 drugs that cost around $1,000 per month before insurance...